Delivery Order SPE2DR25D3111-SPE2DR26FF3VX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion in a 30-count package on April 24, 2025, with a ceiling value of $1,221.73 and a completion date of April 25, 2025. This delivery order represents a firm fixed-price, non-set-aside contract executed as a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The vendor, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,541.08 for Restasis 0.05% Eye Emulsion (30-count units) on May 6, 2025, with an ultimate completion date of May 7, 2025. This firm fixed-price delivery order represents a non-competitive procurement under a larger indefinite delivery contract vehicle. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $4,871.29 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30 single-dose units) on December 17, 2025, with an ultimate completion date of December 18, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a $10,783.83 firm fixed-price delivery order for Restasis 0.05% Eye Emulsion (60 units), with an ultimate completion date of December 5, 2025. This is a competitively awarded, non-set-aside contract with performance taking place at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $23,799.46 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60 count) on May 8, 2025, with completion scheduled for May 9, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Restasis is a prescription ophthalmic medication used to treat dry eye disease, representing part of...
- The Defense Logistics Agency awarded a delivery order valued at $18,986.97 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified pharmaceutical distributors....
- The Defense Logistics Agency awarded a $3,018.16 delivery order to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $6,297.40 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (60-unit package). This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by July 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Restasis 0.05% eye emulsion in 60-unit quantities, with a ceiling value of $5,081.08 and an ultimate completion date of December 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $6,110.43 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Restasis 0.05% Eye Emulsion in 30-unit quantities. This is a firm fixed price delivery order with an ultimate completion date of September 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competitive procurement under AmerisourceBergen's existing indefinite delivery contract...
- SPE2DR25D3111Indefinite Delivery Contract
- SPE2DR25D3111-SPE2DR26FF3VXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,013.75 to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (30 single-use vials) on January 8, 2026, with an ultimate completion date of January 9, 2026. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. AmerisourceBergen Drug Corp operates as a subsidiary of parent company Cencora, Inc., a leading pharmaceutical distributor providing medical products and healthcare solutions to federal government agencies. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive prime vendor contract enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. Restasis, an ophthalmic medication used to treat dry eye disease, represents a routine pharmaceutical supply requirement within this global medical support framework serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 1/7/26 |